Skip to main content

Table 4 Treatments during hospital stay and clinical outcomes of the study patients

From: Clinical outcomes of COVID-19 in Wuhan, China: a large cohort study

  Not severe patients at admission (n = 1102) Non-progressors (n = 841) Progressors (n = 261) p value Severe patients (n = 349) Survivor (n = 192) Non-survivor (n = 157) p value
Treatments, n (%)
 Antibiotic 905 (87.1) 690 (84.9) 215 (95.1) < 0.0001 287 (95.4) 169 (97.1) 118 (92.9) 0.0865
 Antifungal 44 (4.2) 22 (2.7) 22 (9.7) < 0.0001 28 (9.3) 13 (7.5) 15 (11.8) 0.2005
 Antiviral 654 (63.0) 501 (61.6) 153 (67.7) 0.0943 180 (59.8) 125 (71.8) 55 (43.3) < 0.0001
 Glucocorticoids 251 (24.2) 144 (17.7) 107 (47.4) < 0.0001 145 (48.2) 69 (39.7) 76 (59.8) 0.0005
 Oxygen therapy, n (%)     < 0.0001     < 0.0001
  None 203 (18.4) 201 (23.9) 2 (0.8)   2 (0.6) 2 (1.0) 0  
  Nasal cannula 792 (71.9) 634 (75.4) 158 (60.5)   158 (45.3) 142 (74.0) 16 (10.2)  
  Mask oxygen 17 (1.5) 4 (0.5) 13 (5.0)   23 (6.6) 16 (8.3) 7 (4.5)  
  High-flow nasal cannula 25 (2.3) 1 (0.1) 24 (9.2)   59 (16.9) 23 (12.0) 36 (22.9)  
  Non-invasive mechanical ventilation 34 (3.1) 0 (0.0) 34 (13.0)   62 (17.8) 4 (2.1) 58 (36.9)  
  Invasive mechanical ventilation 28 (2.5) 1 (0.1) 27 (10.3)   41 (11.8) 5 (2.6) 36 (22.9)  
  ECMO 3 (0.3) 0 (0.0) 3 (1.2)   4 (1.2) 0 (0.0) 4 (2.6)  
Outcomes
 Duration of MV (IQR), days 4 (2.0, 8.0) 0 4 (2.0, 8.0)   5 (2.0, 8.0) 6 (5.0, 9.0) 4 (2.0, 8.0) 0.1563
 Duration of ICU stay (IQR), days 0 0 6 (3.0, 10.0)   6 (3.0, 10.5) 7 (4.0, 11.0) 5 (2.0, 9.0) 0.0522
 Duration of in-hospital stay (IQR), days 11 (8.00, 15.00) 11 (8.0, 14.0) 12 (8.0, 16.0) 0.0021 11 (7, 16) 14 (10.0, 18.0) 8 (4.0, 12.0) < 0.0001
 In-hospital mortality, n (%) 91 (8.26) 0 (0.0) 91 (34.9) < 0.0001 157 (45.0) 0 (0.0) 157 (100.0) < 0.0001
  1. ECMO extracorporeal membrane oxygenation, ICU intensive care unit, MV mechanical ventilation